Injectable extended-release naltrexone for opioid dependence

The Lancet

Volumn 378, Issue 9792, 2011, Pages 664-665

  Woody, George E ^a   Metzger, David S ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

METHADONE; NALTREXONE; PLACEBO; PRODETOXON; UNCLASSIFIED DRUG;

DRUG OVERDOSE; DRUG RELEASE; DRUG SAFETY; EXTENDED DRUG RELEASE; HUMAN; LETTER; MORTALITY; OPIATE ADDICTION; PATIENT EDUCATION; PRIORITY JOURNAL;

EID: 80051970254     PISSN: 0140-6736     EISSN: 1474-547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(11)61330-5     Document Type: Letter

References (5)

1. D Wolfe, MP Carrieri, N Dasgupta, A Wodak, R Newman, RD Bruce Concerns about injectable naltrexone for opioid dependence Lancet 377 2011 1468 1470
2. K Miotto, MJ McCann, RA Rawson, D Frosch, W Ling Overdose, suicide attempts and death among a cohort of naltrexone-treated opioid addicts Drug Alcohol Dep 45 1997 131 134 (Pubitemid 27246414)
3. E Digiusto, A Shakeshaft, A Ritter, S O'Brien, R Mattick NEPOD Research Group Serious adverse events in the Australian National Evaluation of Pharmacotherapies for Opioid Dependence (NEPOD) Addiction 99 2004 450 460 (Pubitemid 38496661)
4. A Gibson, LJ Degenhardt Mortality related to pharmacotherapies for opioid dependence: a comparative analysis of coronial records Drug Alcohol Rev 26 2007 405 410
5. Krupitsky E, Zvartau E, Woody G. Naltrexone for opiate dependence: oral, implantable, and injectable. Presented at annual meeting of the American Association for the Treatment of Opioid Dependence; Chicago, IL, USA; Oct 23-27, 2010.